PubRank

Heidrun Potschka

Author PubWeight™ 58.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005 3.19
2 Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005 2.44
3 Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005 2.43
4 Functional inactivation of a fraction of excitatory synapses in mice deficient for the active zone protein bassoon. Neuron 2003 2.31
5 Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 2007 1.97
6 Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002 1.60
7 Anticonvulsant effects of transcranial direct-current stimulation (tDCS) in the rat cortical ramp model of focal epilepsy. Epilepsia 2006 1.41
8 Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2006 1.18
9 Neurogenesis in the adult rat piriform cortex. Neuroreport 2006 1.12
10 Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. Neuropharmacology 2007 1.11
11 Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 2002 1.11
12 Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem 2005 1.07
13 Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2006 1.05
14 COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2009 1.03
15 Finding a better drug for epilepsy: antiepileptogenesis targets. Epilepsia 2012 0.99
16 Modulation of neurogenesis by targeted hippocampal irradiation fails to affect kindling progression. Hippocampus 2010 0.98
17 Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 2006 0.96
18 Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J Pharmacol Exp Ther 2009 0.95
19 Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009 0.94
20 Targeting epileptogenesis-associated induction of neurogenesis by enzymatic depolysialylation of NCAM counteracts spatial learning dysfunction but fails to impact epilepsy development. J Neurochem 2008 0.93
21 The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. Eur J Neurosci 2004 0.91
22 Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. Epilepsia 2004 0.88
23 Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res 2002 0.88
24 Effect of aging on neurogenesis in the canine brain. Aging Cell 2008 0.88
25 Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res 2004 0.88
26 Epileptogenesis and neuropathology after different types of status epilepticus induced by prolonged electrical stimulation of the basolateral amygdala in rats. Epilepsy Res 2003 0.87
27 Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia 2002 0.86
28 In vivo imaging of dopamine receptors in a model of temporal lobe epilepsy. Epilepsia 2009 0.85
29 Impact of the PSA-NCAM system on pathophysiology in a chronic rodent model of temporal lobe epilepsy. Neurobiol Dis 2007 0.83
30 Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur J Pharmacol 2002 0.82
31 Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage 2009 0.82
32 Targeting the prostaglandin E2 EP1 receptor and cyclooxygenase-2 in the amygdala kindling model in mice. Epilepsy Res 2010 0.81
33 MAP-kinase-activated protein kinase 2 expression and activity is induced after neuronal depolarization. Eur J Neurosci 2008 0.81
34 Lacosamide treatment following status epilepticus attenuates neuronal cell loss and alterations in hippocampal neurogenesis in a rat electrical status epilepticus model. Epilepsia 2013 0.81
35 Targeting the endocannabinoid system in the amygdala kindling model of temporal lobe epilepsy in mice. Epilepsia 2011 0.80
36 The novel antiepileptic drug imepitoin compares favourably to other GABA-mimetic drugs in a seizure threshold model in mice and dogs. Pharmacol Res 2013 0.80
37 In vivo down-regulation of mouse brain capillary P-glycoprotein: a preliminary investigation. Neurosci Lett 2009 0.80
38 Hydantoin-substituted 4,6-dichloroindole-2-carboxylic acids as ligands with high affinity for the glycine binding site of the NMDA receptor. J Med Chem 2003 0.80
39 Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model. Epilepsy Res 2009 0.80
40 [11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness. Nucl Med Biol 2013 0.79
41 Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia 2010 0.79
42 The role of p-glycoprotein in psychiatric disorders: a reliable guard of the brain? Cent Nerv Syst Agents Med Chem 2011 0.79
43 The erythropoietin-derived peptide mimetic pHBSP affects cellular and cognitive consequences in a rat post-status epilepticus model. Epilepsia 2011 0.79
44 Add-on treatment with verapamil in pharmacoresistant canine epilepsy. Epilepsia 2011 0.79
45 mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy. Neuropharmacology 2006 0.79
46 Amygdala-kindling does not induce a persistent loss of GABA neurons in the substantia nigra pars reticulata of rats. Brain Res 2004 0.78
47 Newborn neurons with hilar basal dendrites hallmark epileptogenic networks. Neuroreport 2007 0.78
48 Impact of the erythropoietin-derived peptide mimetic Epotris on the histopathological consequences of status epilepticus. Epilepsy Res 2011 0.78
49 Long-term genetic fate mapping of adult generated neurons in a mouse temporal lobe epilepsy model. Neurobiol Dis 2012 0.78
50 Retarded kindling progression in mice deficient in the extracellular matrix glycoprotein tenascin-R. Epilepsia 2008 0.77
51 Dynamic regulation of P-glycoprotein in human brain capillaries. Mol Pharm 2013 0.77
52 CNS transporters and drug delivery in epilepsy. Curr Pharm Des 2014 0.76
53 Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. Eur J Pharmacol 2009 0.76
54 Allele-specific polymerase chain reaction diagnostic test for the functional MDR1 polymorphism in dogs. Vet J 2007 0.76
55 Cellular localization of Y-box binding protein 1 in brain tissue of rats, macaques, and humans. BMC Neurosci 2009 0.76
56 Are neuronal nicotinic receptors a target for antiepileptic drug development? Studies in different seizure models in mice and rats. Eur J Pharmacol 2003 0.76
57 Impact of the neural cell adhesion molecule-derived peptide FGL on seizure progression and cellular alterations in the mouse kindling model. ACS Chem Neurosci 2014 0.75
58 Polymorphic variants of the multidrug resistance gene Mdr1a and response to antiepileptic drug treatment in the kindling model of epilepsy. Eur J Pharmacol 2006 0.75
59 Polysialic acid affects pathophysiological consequences of status epilepticus. Neuroreport 2010 0.75
60 The CNTF-derived peptide mimetic Cintrofin attenuates spatial-learning deficits in a rat post-status epilepticus model. Neurosci Lett 2013 0.75
61 Impact of the NCAM derived mimetic peptide plannexin on the acute cellular consequences of a status epilepticus. Neurosci Lett 2011 0.75
62 Brain penetration and anticonvulsant efficacy of intranasal phenobarbital in rats. Epilepsia 2008 0.75